Polycythemia vera

Polycythemia vera
Other namesPolycythaemia vera (PV, PCV), erythremia, primary polycythemia, Vaquez disease, Osler-Vaquez disease, polycythemia rubra vera[1]
Blood smear from a patient with polycythemia vera
SpecialtyOncology, hematology

In oncology, polycythemia vera (PV) is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells.[1] The majority of cases[2] are caused by mutations in the JAK2 gene, most commonly resulting in a single amino acid change in its protein product from valine to phenylalanine at position 617.[3]

Most of the health concerns associated with polycythemia vera are caused by the blood being thicker as a result of the increased red blood cells. It is more common in the elderly and may be symptomatic or asymptomatic. Common signs and symptoms include itching (pruritus), and severe burning pain in the hands or feet that is usually accompanied by a reddish or bluish coloration of the skin. Patients with polycythemia vera are more likely to have gouty arthritis. Treatment consists primarily of phlebotomy as well as oral chemotherapy and emerging treatments like long-acting interferon formulations.

Signs and symptoms

Erythromelalgia is a rare symptom of PV, here present in a patient with longstanding polycythemia vera. Note reddish limbs and swelling.

People with polycythemia vera can be asymptomatic.[4] Clinical symptoms of polycythemia vera are mostly due to hyperviscosity of blood. A classic symptom of polycythemia vera is pruritus or itching, particularly after exposure to warm water (such as when taking a bath),[5] which may be due to abnormal histamine release[6][7] or prostaglandin production.[8] Such itching is present in approximately 40% of patients with polycythemia vera.[9] Gouty arthritis may be present in up to 20% of patients.[9] Peptic ulcer disease is also common in patients with polycythemia vera; most likely due to increased histamine from mast cells, but may be related to an increased susceptibility to infection with the ulcer-causing bacterium H. pylori.[10]

A classic symptom of polycythemia vera (and the related myeloproliferative disease essential thrombocythemia) is erythromelalgia.[11] This is a burning pain in the hands or feet, usually accompanied by a reddish or bluish coloration of the skin. Erythromelalgia is caused by an increased platelet count or increased platelet "stickiness" (aggregation), resulting in the formation of tiny blood clots in the vessels of the extremity; it responds rapidly to treatment with aspirin.[12][13] Splenomegaly may cause the spleen to be palpable in some patients, which has been reported by Lee et al. (2022) to be associated with both the V617F mutation and the development of myelofibrosis.[14]

Pathophysiology

Polycythemia vera (PV), being a primary polycythemia (increase in the fraction of volume occupied by red cells in the blood), is caused by neoplastic proliferation and maturation of erythroid, megakaryocytic and granulocytic elements to produce what is referred to as panmyelosis. In contrast to secondary polycythemias, PV is associated with a low serum level of the hormone erythropoietin (EPO). Instead, PV cells often carry activating mutation in a tyrosine kinase–encoding gene, JAK2, which acts in signaling pathways of the EPO receptor, making those cells proliferate independently from EPO.[15][page needed]

Diagnosis

Diagnostic criteria for polycythemia vera were modified by the World Health Organization in 2016.[16] The WHO criteria for polycythemia vera are specifically outlined in Table 4, and emphasis is given to accurate histological observations as proven predictors in the prognosis of the disease.

As summarized by Verstovek following the 2016 European Hematology Association Congress,[17] there are 3 major criteria for PV diagnosis:

  1. The first is a very high red blood cell count, which is usually identified by elevated levels of hemoglobin or hematocrit;
  2. A bone marrow biopsy that shows hypercellularity and abnormalities in megakaryocytes; and
  3. The presence of a mutation in the Janus kinase 2 (JAK2) gene.

Patients usually have a very low level of erythropoietin, a growth factor that increases the production of red blood cells, which may be considered a minor diagnostic feature.

A mutation in the JAK2 kinase (V617F) is strongly associated with polycythemia vera.[18][19] While it is a JAK2 V617F mutation in 95% of patients, JAK2 exon 12 mutations have also been observed.[20] The V617F mutation is not inherited, but develops as a somatic mutation in the erythroid progenitor cells.[21] Some patients may lose the normal allele in the diseased cells entirely together with the short arm of chromosome 9 (9p), likely due to mitotic recombination causing copy-neutral loss of heterozygosity.[22] While the JAK2 V617F mutation is generally sporadic (random), a certain inherited haplotype of JAK2 has been associated with its development.[23][24]

People with untreated polycythemia vera have a substantial risk of Budd-Chiari syndrome (hepatic vein thrombosis).[25]

Treatment

Untreated, polycythemia vera can be fatal, with the median survival in patients being 1.5-3 years.[26][27][28] Data on the effect of life-span of an individual with treated polycythemia vera is inconclusive due to the rarity of the disease. Studies show the median survival rate of controlled Polycythemia Vera ranges from 10 to 20 years; however, most observations are of people diagnosed in their 60s. Patients live close to a normal life expectancy.[29]

Frequent blood withdrawals (phlebotomy) are one form of treatment, which often may be combined with other therapies. The removal of blood from the body induces iron deficiency, thereby decreasing the hemoglobin / hematocrit level, and reducing the risk of blood clots. Phlebotomy is typically performed to bring their hematocrit (red blood cell percentage) down below 45 for men or 42 for women.[30] It has been observed that phlebotomy also reduces cognitive impairment.[31]

Medications are also used which reduce the number of red blood cells. These include hydroxyurea and interferon therapy, among others.[32] The tendency of some practitioners to avoid chemotherapy if possible, especially in young patients, is a result of research indicating possible increased risk of transformation to acute myelogenous leukemia (AML). While hydroxyurea is considered a safer chemotherapy in this aspect, there is still some debate about its long-term safety.[33]

There are indications that the lung cancer drug erlotinib may be an additional treatment option for those with certain genetic markers.[34]

Ruxolitinib (brand name Jakafi), a Janus kinase 2 (JAK2) inhibitor, is also used to treat polycythemia.[35]

Ropeginterferon alfa-2b (Besremi) was approved for medical use in the European Union in February 2019,[36] and in the United States in November 2021.[37][38] Ropeginterferon alfa-2b is the first medication approved by the U.S. Food and Drug Administration (FDA) to treat polycythemia vera that peo

Epidemiology

Polycythemia vera occurs in all age groups,[39] although the incidence increases with age. One study found the median age at diagnosis to be 60 years,[9] while a Mayo Clinic study in Olmsted County, Minnesota found that the highest incidence was in people aged 70–79 years.[40] The overall incidence in the Minnesota population was 1.9 per 100,000 person-years, and the disease was more common in men than women.[40] A cluster around a toxic site was confirmed in northeast Pennsylvania in 2008.[41]

Notable deaths

References

  1. ^ a b "polycythemia vera." at Encyclopædia Britannica. 2010. Encyclopædia Britannica Online. 21 Sep. 2010
  2. ^ Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. (2016). "Targeted deep sequencing in polycythemia vera and essential thrombocytopenia". Blood Advances. 1 (1): 21–30. doi:10.1182/bloodadvances.2016000216. PMC 5744051. PMID 29296692.
  3. ^ Regimbeau M, Mary R, Hermetet F, Girodon F (2022). "Genetic Background of Polycythemia Vera". Genes. 13 (4). doi:10.3390/genes13040637. PMC 9027017. PMID 35456443. Art. No. 637.
  4. ^ [Polycythemia vera EBSCO database] verified by URAC; accessed from Mount Sinai Hospital, New York
  5. ^ Saini KS, Patnaik MM, Tefferi A (2010). "Polycythemia vera-associated pruritus and its management". Eur J Clin Invest. 40 (9): 828–34. doi:10.1111/j.1365-2362.2010.02334.x. PMID 20597963. S2CID 13638890.
  6. ^ Steinman H, Kobza-Black A, Lotti T, Brunetti L, Panconesi E, Greaves M (1987). "Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge". Br J Dermatol. 116 (3): 329–33. doi:10.1111/j.1365-2133.1987.tb05846.x. PMID 3567071. S2CID 22068469.
  7. ^ Jackson N, Burt D, Crocker J, Boughton B (1987). "Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus". Br J Dermatol. 116 (1): 21–9. doi:10.1111/j.1365-2133.1987.tb05787.x. PMID 3814512. S2CID 38261640.
  8. ^ Fjellner B, Hägermark O (1979). "Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement". Acta Derm Venereol. 59 (6): 505–12. doi:10.2340/0001555559505512. PMID 94209. S2CID 6909368.
  9. ^ a b c Berlin NI (1975). "Diagnosis and classification of polycythemias". Semin Hematol. 12 (4): 339–51. PMID 1198126.
  10. ^ Torgano G, Mandelli C, Massaro P, Abbiati C, Ponzetto A, Bertinieri G, Bogetto S, Terruzzi E, de Franchis R (2002). "Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori". Br J Haematol. 117 (1): 198–202. doi:10.1046/j.1365-2141.2002.03380.x. PMID 11918555.
  11. ^ van Genderen P, Michiels J (1997). "Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera". Semin Thromb Hemost. 23 (4): 357–63. doi:10.1055/s-2007-996109. PMID 9263352.
  12. ^ Michiels J (1997). "Erythromelalgia and vascular complications in polycythemia vera". Semin Thromb Hemost. 23 (5): 441–54. doi:10.1055/s-2007-996121. PMID 9387203.
  13. ^ Landolfi R, Ciabattoni G, Patrignani P, Castellana M, Pogliani E, Bizzi B, Patrono C (1992). "Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo". Blood. 80 (8): 1965–71. doi:10.1182/blood.V80.8.1965.1965. PMID 1327286.
  14. ^ Lee MW, Yeon SH, Ryu H, Song IC, Lee HJ, Yun HJ, Kim SY, Lee JE, Shin KS, Jo DY (2022). "Volumetric Splenomegaly in Patients With Polycythemia Vera". Journal of Korean Medical Science. 37 (11). doi:10.3346/jkms.2022.37.e87. PMC 8938613. PMID 35315598. Art. No. e87.
  15. ^ Kumar, V, Abbas AK, Fausto N, Mitchell RN, eds. (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. ISBN 978-1-4160-2973-1.
  16. ^ Daniel A. Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J. Borowitz; Michelle M. Le Beau; Clara D. Bloomfield; Mario Cazzola; James W. Vardiman (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. PMID 27069254. S2CID 18338178.
  17. ^ Verstovsek, S. (2016). "Highlights in polycythemia vera from the 2016 EHA congress". Clin Adv Hematol Oncol. 14 (10): 810–813. PMID 27930632.
  18. ^ Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet. 365 (9464): 1054–61. doi:10.1016/S0140-6736(05)71142-9. PMID 15781101. S2CID 24419497.
  19. ^ Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005). "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis". Cancer Cell. 7 (4): 387–97. doi:10.1016/j.ccr.2005.03.023. PMID 15837627.
  20. ^ Verstovsek, S. (2016). "Highlights in polycythemia vera from the 2016 EHA congress". Clin Adv Hematol Oncol. 14 (10): 810–813. PMID 27930632.
  21. ^ Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ (2005). "Identification of an Acquired JAK2 Mutation in Polycythemia Vera". Journal of Biological Chemistry. 280 (24): 22788–22792. doi:10.1074/jbc.C500138200. PMC 1201515. PMID 15863514.
  22. ^ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005). "A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders". The New England Journal of Medicine. 352 (17): 1779–1790. doi:10.1056/NEJMoa051113. PMID 15858187.
  23. ^ Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC (2009). "JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms". Nature Genetics. 41 (4): 446–449. doi:10.1038/ng.334. PMC 4120192. PMID 19287382.
  24. ^ Hirvonen EA, Pitkänen E, Hemminki K, Aaltonen LA, Kilpivaara O (2017). "Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera". Human Genomics. 11 (1). doi:10.1186/s40246-017-0102-x. PMC 5397753. PMID 28427458. Art. No. 6.
  25. ^ Thurmes PJ, Steensma DP (July 2006). "Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis". Eur. J. Haematol. 77 (1): 57–60. doi:10.1111/j.1600-0609.2006.00667.x. PMID 16827884. S2CID 37383942.
  26. ^ Mayo Clinic staff. "Polycythemia vera - MayoClinic.com". Polycythemia vera: Definition. Mayo Clinic. Retrieved 2011-09-03.
  27. ^ "What Is Polycythemia Vera?". National Heart, Lung and Blood Institute. Retrieved 2011-09-03.
  28. ^ "Polycythemia Vera Follow-up". Retrieved 2011-09-03.
  29. ^ Verstovsek, S. (2016). "Highlights in polycythemia vera from the 2016 EHA congress". Clin Adv Hematol Oncol. 14 (10): 810–813. PMID 27930632.
  30. ^ Streiff MB, Smith B, Spivak JL (2002). "The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns". Blood. 99 (4): 1144–9. doi:10.1182/blood.V99.4.1144. PMID 11830459.
  31. ^ Di Pollina L, Mulligan R, Juillerat Van der Linden A, Michel JP, Gold G (2000). "Cognitive impairment in polycythemia vera: partial reversibility upon lowering of the hematocrit". Eur. Neurol. 44 (1): 57–9. doi:10.1159/000008194. PMID 10894997. S2CID 40928145.
  32. ^ "Polycythemia vera - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2022-03-11.
  33. ^ Björkholm, M; Derolf, AR; Hultcrantz, M; et al. (10 June 2011). "Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms". Journal of Clinical Oncology. 29 (17): 2410–5. doi:10.1200/JCO.2011.34.7542. PMC 3107755. PMID 21537037.
  34. ^ Li Z, Xu M, Xing S, Ho W, Ishii T, Li Q, Fu X, Zhao Z (2007). "Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth". J Biol Chem. 282 (6): 3428–32. doi:10.1074/jbc.C600277200. PMC 2096634. PMID 17178722.
  35. ^ Tefferi, A; Vannucchi, AM; Barbui, T (10 January 2018). "Polycythemia vera treatment algorithm 2018". Blood Cancer Journal. 8 (1): 3. doi:10.1038/s41408-017-0042-7. PMC 5802495. PMID 29321547.
  36. ^ "Besremi EPAR". European Medicines Agency (EMA). 12 December 2018. Retrieved 14 November 2021.
  37. ^ "FDA Approves Treatment for Rare Blood Disease". U.S. Food and Drug Administration (FDA) (Press release). 12 November 2021. Retrieved 12 November 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  38. ^ "U.S. FDA Approves Besremi (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera" (Press release). PharmaEssentia. 12 November 2021. Retrieved 14 November 2021 – via Business Wire.
  39. ^ Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M (2003). "Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia". Haematologica. 88 (1): 13–8. PMID 12551821.
  40. ^ a b Anía B, Suman V, Sobell J, Codd M, Silverstein M, Melton L (1994). "Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989". Am J Hematol. 47 (2): 89–93. doi:10.1002/ajh.2830470205. PMID 8092146. S2CID 31536624.
  41. ^ MICHAEL RUBINKAM (2008). "Cancer cluster confirmed in northeast Pennsylvania". Associated Press. Archived from the original on September 2, 2008.
  42. ^ Yetter, Deborah (May 16, 2020). "Phyllis George, former Kentucky first lady and Miss America, dies at 70". The Courier-Journal. Retrieved May 16, 2020.
  43. ^ Harrington, Jim (March 9, 2022). "'Gifted artist' Ron Miles dies of a rare blood disorder at 58". The Mercury News. Retrieved March 10, 2022.
  44. ^ Allan Kozinn (January 19, 2005). "Nell Rankin Is Dead at 81; Mezzo-Soprano With Met". The New York Times.

Read other articles:

Dieser Artikel behandelt die Arbeiter-Zeitung der österreichischen Sozialdemokratie in Wien. Für weitere Publikationen dieses Namens siehe Arbeiter-Zeitung (Begriffsklärung). Arbeiter-Zeitung, AZ/Tagblatt, Neue AZ Beschreibung österreichische Parteizeitung (bis 1989); unabhängiges Tagblatt (1989 bis zur Einstellung) Fachgebiet „Organ“/„Zentralorgan“ der österreichischen Sozialdemokratie Sprache Deutsch Verlag zuletzt Druck- und Verlagsanstalt „Vorwärts“, Kommanditgesellsch...

 

Piala Suzuki AFF 2010Logo resmi Piala Suzuki AFF 2010Informasi turnamenTuan rumah Indonesia VietnamJadwalpenyelenggaraan1–29 DesemberJumlahtim peserta8Tempatpenyelenggaraan4 + 1 (di 4 + 1 kota)Hasil turnamenJuara Malaysia (gelar ke-1)Tempat kedua IndonesiaStatistik turnamenJumlahpertandingan18Jumlah gol51 (2,83 per pertandingan)Jumlahpenonton777.000 (43.167 per pertandingan)Pemain terbaik Firman UtinaPencetak golterbanyak Mohd Safee Bin Mohd Sali (5 gol)Penghargaanf...

 

The following is a list of important scholarly resources related to John Quincy Adams, the sixth president of the United States. Secondary sources This article is part of a series aboutJohn Quincy Adams Birthplace Early life Family Adams Quincy Electoral history Bibliography Historical reputation United States Secretary of State Treaty of Ghent Adams–Onís Treaty Treaty of 1818 6th President of the United States Presidency Inauguration Judicial Appointments Foreign policy Tariff of 1828 Fi...

Penari di Biskra, diterbitkan oleh National Geographic bulan Maret 1917. Lambang lama Koordinat: 34°51′N 5°44′E / 34.850°N 5.733°E / 34.850; 5.733 Biskra (bahasa Arab: بسكرة ; bahasa Berber: Tibeskert) ialah ibu kota Provinsi Biskra, Aljazair. Pada tahun 2007, penduduknya mencapai 207.987. Sampai tahun 1935, Biskra adalah kota pedalaman, permukiman penting oasis Sahara yang dialiri secara terputus oleh Oued Biskra. Kota ini terletak di selatan jaringan KA ...

 

Cave in the Black Hills of South Dakota, USA Jewel Cave National MonumentIUCN category III (natural monument or feature)Visitors and guide inside Jewel CaveShow map of South DakotaShow map of the United StatesLocationCuster County, South Dakota, U.S.Nearest cityCuster, South DakotaCoordinates43°43′46″N 103°49′46″W / 43.72944°N 103.82944°W / 43.72944; -103.82944Area1,273 acres (5.15 km2)[1]CreatedFebruary 7, 1908 (1908-Februa...

 

American journalist Lea GabrielleBornLea Gabrielle Potts[1] (1975-03-19) March 19, 1975 (age 49)Alexandria, Virginia, US[2]EducationUnited States Naval Academy (1997)[1]Occupation(s)Journalist and Naval aviator Lea Gabrielle (born March 19, 1975) is a former U.S. Diplomat who served as the Special Envoy and Coordinator of the Global Engagement Center at the U.S. Department of State from 2019-2021.[3] She formerly served in the United States Navy for twelve...

ملك بابل أداد شوما أصر   ملك بابل فترة الحكمح. 1216–1187 ق م معلومات شخصية تاريخ الميلاد القرن 13 ق.م  تاريخ الوفاة القرن 12 ق.م  مواطنة بابل  الأب كشتيلياش الرابع  عائلة كاشية الحياة العملية المهنة حاكم  تعديل مصدري - تعديل   أداد شوما أصر هو ملك بابلي والملك ال32 ل...

 

1983 filmMerry Christmas, Mr. LawrenceJapanese theatrical release posterDirected byNagisa ŌshimaScreenplay by Nagisa Ōshima Paul Mayersberg Based onThe Seed and the Sower1963 novelby Sir Laurens van der PostProduced byJeremy ThomasStarring David Bowie Tom Conti Ryuichi Sakamoto Takeshi Kitano Jack Thompson CinematographyToichiro NarushimaEdited byTomoyo ŌshimaMusic byRyuichi SakamotoProductioncompanies National Film Trustee Company Antares-Nova N.V. Recorded Picture Company Oshima Product...

 

Open cluster in the constellation Cassiopeia This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: Trumpler 3 – news · newspapers · books · scholar · JSTOR (December 2016) Trumpler 3Trumpler 3 as seen from the Stellarium SoftwareObservation data (J2000.0 epoch)Right ascension03h 12m 00sDeclination+6...

Warbringer Paese d'origine Stati Uniti GenereThrash metal Periodo di attività musicale2004 – in attività EtichettaCentury Media Records Album pubblicati6 Studio6 Sito ufficiale Modifica dati su Wikidata · Manuale Gli Warbringer sono una band Thrash metal statunitense formatasi a Newbury Park (California) nel 2004, che si distingue per il sound estremo e la tecnica della musica che propone. Indice 1 Storia del gruppo 2 Formazione 2.1 Formazione attuale 2.2 Ex ...

 

Collegiate sports club in the United States This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: UNC Greensboro Spartans – news · newspapers · books · scholar · JSTOR (March 2008) (Learn how and when to remove this message) UNC Greensboro SpartansUniversityUniversity of North Carolina at GreensboroConferenceSouth...

 

  提示:此条目页的主题不是中國—瑞士關係。   關於中華民國與「瑞」字國家的外交關係,詳見中瑞關係 (消歧義)。 中華民國—瑞士關係 中華民國 瑞士 代表機構駐瑞士台北文化經濟代表團瑞士商務辦事處代表代表 黃偉峰 大使[註 1][4]處長 陶方婭[5]Mrs. Claudia Fontana Tobiassen 中華民國—瑞士關係(德語:Schweizerische–republik china Beziehungen、法�...

دريم ووركس أنيميشنDreamWorks Animation LLC (بالإنجليزية) الشعارمعلومات عامةالبلد  الولايات المتحدة التأسيس 1994 النوع استوديو رسوم متحركة — شركة إنتاج أفلام — استوديو أفلام — شركة عمومية محدودة الشكل القانوني شركة عمومية محدودة المقر الرئيسي غلينديل حلت محل Amblimation (en) موقع الويب dr...

 

Surface treatment technique Milled edge of a 1951 Hong Kong 50¢ coin Reeding or milling is a technique wherein a number of narrow ridges called reeds are carved or milled into a surface with a castaing machine.[1][2] Numismatics Milled edge of a German 2 euro coin, embossed with Germany's unofficial national motto Einigkeit und Recht und Freiheit In numismatics, reeded edges are often referred to as ridged or grooved (American usage), or milled (British usage).[3] Som...

 

Cara kerja segitiga pembalik Segitiga pembalik dalam istilah perkeretaapian adalah tatanan rel kereta api berbentuk segitiga dengan wesel di setiap ujungnya. Segitiga pembalik dapat ditemui di beberapa stasiun tertentu dan berfungsi untuk memutar bakal pelanting (lokomotif, kereta, gerbong dan lainnya) di stasiun atau dipo yang tidak memiliki pemutar rel (turntable), seperti Stasiun Semarang Poncol (walaupun sekarang dipo lokomotifnya sudah dilengkapi turntable) dan Stasiun Ketapang (yang dah...

Political designation in Ancient Rome Novus homo or homo novus (lit. 'new man'; pl.: novi homines or homines novi) was the term in ancient Rome for a man who was the first in his family to serve in the Roman Senate or, more specifically, to be elected as consul. When a man entered public life on an unprecedented scale for a high communal office, then the term used was novus civis (plural: novi cives) or new citizen.[1] History Cicero In the Early Republic, tradition held that bo...

 

ГородВерхнеднепровскукр. Верхньодніпровськ Памятник славы Флаг Герб 48°38′59″ с. ш. 34°19′50″ в. д.HGЯO Страна  Украина Область Днепропетровская Район Каменский Община Верхнеднепровская городская Городской голова Лебедь Геннадий Николаевич История и географи�...

 

Menteri Kesehatan MalaysiaMenteri Kesihatan Malaysia منتري كصيحتن مليسياLambangPetahanaDzulkefly Ahmadsejak 12 Desember 2023Kementerian KesehatanGelarYang Berhormat Menteri(Yang Terhormat Menteri)Ditunjuk olehYang di-Pertuan Agong atas petunjuk Perdana Menteri MalaysiaDibentuk9 Agustus 1955; 68 tahun lalu (1955-08-09)Pejabat pertamaLeong Yew KohSitus webwww.moh.gov.my Berikut adalah daftar orang yang pernah menjabat sebagai Menteri Kesehatan (bahasa Melayu: Ment...

2013 EP by Austin MahoneExtended PlayEP by Austin MahoneReleasedMay 29, 2013 (2013-05-29)Recorded2012–2013GenreTeen popLength20:42Label Chase Republic Producer DJ Frank E Mike Fresh Trent Mazur Bei Maejor Austin Mahone Bruce Robinson Steve Mac Matt Mahaffey Austin Mahone chronology Extended Play(2013) The Secret(2014) Singles from Extended Play Say SomethinReleased: June 5, 2012 Say You're Just a FriendReleased: December 3, 2012 Deluxe editionThe deluxe edition artwor...

 

Intermediate appellate court of Illinois Tool Works Parts of this article (those related to 2nd-5th Districts) need to be updated. The reason given is: Illinois redistricted appellate divisions. Please help update this article to reflect recent events or newly available information. (March 2024) Chicago (1st)Elgin (2nd)Ottawa (3rd)Springfield (4th)Mount Vernon (5th)class=notpageimage| Court locations The Illinois Appellate Court is the court of first appeal for civil and criminal cases rising...